Key result
T-TEER substantially reduces severity and improves quality of life in symptomatic severe TR.
Why the study?
Tricuspid regurgitation has historically been undertreated with limited surgical survival benefit, leaving an unmet need for minimally invasive therapies, while the role of T-TEER as a disease-modifying versus palliative intervention remains debated.
Does transcatheter edge-to-edge repair (T-TEER) improve outcomes in patients with symptomatic severe or greater tricuspid regurgitation unsuitable for surgery?
Does transcatheter edge-to-edge repair (T-TEER) improve outcomes in patients with symptomatic severe or greater tricuspid regurgitation unsuitable for surgery?
T-TEER provides substantial symptom relief and quality of life improvement for severe TR patients unsuitable for surgery, acting as a bridge between palliation and potential disease-modifying therapy.
Supports symptom relief in severe TR; leaves open mortality/HF hospitalization effects pending RCTs.
Tricuspid regurgitation (TR) has historically been undertreated despite its strong association with morbidity and mortality. Surgical correction of isolated TR is not routinely performed and has shown limited survival benefit, leaving a substantial unmet need for minimally invasive therapies. Transcatheter edge-to-edge repair (T-TEER) has emerged as a promising therapeutic option for patients with symptomatic severe or greater (≥severe) TR who are unsuitable for surgery. Recent randomized trials, including the TRILUMINATE Pivotal and the Tri-FR study, and real-world registries consistently demonstrate significant improvements in TR severity, functional status, and quality of life following T-TEER. Although benefits in hard clinical endpoints such as mortality or heart failure hospitalizations remain less conclusive, growing evidence suggests potential prognostic advantage in selected patients, particularly those with preserved or mid-range right ventricular function. Anatomical suitability, RV performance, and optimized patient selection are crucial determinants of success. As ongoing large-scale trials continue to evaluate long-term outcomes, T-TEER currently occupies a therapeutic space between palliative intervention and disease-modifying therapy, providing substantial symptom relief with the potential for broader clinical benefit. This review summarizes current evidence, patient selection strategies, and perspectives on the evolving role of T-TEER in the management of severe TR.
No takes yet. Share an insight, caveat, or question.
Mitsis et al. (2026) studied this question. Transcatheter edge-to-edge repair (T-TEER) substantially improves TR severity and patient quality of life in symptomatic severe tricuspid regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: